US Stock MarketDetailed Quotes
IPA ImmunoPrecise Antibodies
- 1.020
- +0.120+13.33%
Close Aug 16 16:00 ET
- 1.000
- -0.020-1.96%
Post 19:51 ET
27.85MMarket Cap-1321P/E (TTM)
1.037High0.900Low202.80KVolume0.950Open0.900Pre Close197.75KTurnover0.85%Turnover RatioLossP/E (Static)27.30MShares2.60052wk High1.13P/B24.22MFloat Cap0.58052wk Low--Dividend TTM23.74MShs Float33.340Historical High--Div YieldTTM15.22%Amplitude0.580Historical Low0.975Avg Price1Lot Size
ImmunoPrecise Antibodies Stock Forum
Sign in to post a comment
$ImmunoPrecise Antibodies (IPA.US)$ Yes im always looking for them “ Bouncing Cats “ Hehehe! Well here is a cat that bounced on Tuesday and is still moving up! And this is why im always looking for a DCB! Hehehe! Sure hope you see this post? Otherwise it would be totally different! Hehehe! BTW again nice having you around so much this week🤭🤣
1
4
$ImmunoPrecise Antibodies (IPA.US)$
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:
- 8.0% annual interest rate
- Convertible to comm...
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:
- 8.0% annual interest rate
- Convertible to comm...
1
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$ImmunoPrecise Antibodies (IPA.US)$
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve pa...
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve pa...
ImmunoPrecise Antibodies Subsidiary BioStrand Announces Immediate Commercial Offering Of Software With Customizable Interface For AI-Driven Drug Discovery.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...
$ImmunoPrecise Antibodies (IPA.US)$ Reuters· 1 min ago
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery
4
$ImmunoPrecise Antibodies (IPA.US)$
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
$ImmunoPrecise Antibodies (IPA.US)$
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
2
loading...
8
$ImmunoPrecise Antibodies (IPA.US)$ NEWS
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
2
3
$ImmunoPrecise Antibodies (IPA.US)$ NEWS
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
potsy52 : Would this be a possible swing
Trytosaveabit OP potsy52 : Yes I’m swinging it! But I don’t put any belief in analysts PT’s but a lot do! And sometimes when they really increase a PT it can cause a buy spike! Anyway 1 analyst just lowered the PT to 3.00 here. So now you have one analyst with a buy rating with 3.00 PT and another with 3 buy ratings this year and a 9.00 PT! But again I’m am in and swinging it!
potsy52 : Great info/ thanks much
Trytosaveabit OP potsy52 : You’re welcome! GL